In solid-dosage manufacturing lines, methenamine hippurate is handled as a moisture-sensitive active pharmaceutical ingredient whose primary downstream use is urinary antibacterial prophylaxis. Direct compression is selected for oral tablet manufacture when the active load is 1 g of methenamine hippurate per tablet, corresponding to approximately 71–80% w/w of the final core mass before any film coating. The formulation space includes povidone binder at 2–5% w/w, crospovidone disintegrant at 2–4% w/w, colloidal silicon dioxide glidant at 0.2–0.5% w/w, and magnesium stearate lubricant at 0.5–1.5% w/w. All excipients are pre-sieved through a 0.700 mm aperture screen; the API is passed through a 0.500 mm screen to break soft agglomerates before weighing. Blending is conducted in a 1000 L diffusion blender at 12 rpm for 15–20 min, with the lubricant added as a final step and blended for 3–5 min to avoid over-lubrication. The blend is compressed on a 21-station rotary tablet press using 19 mm × 9 mm oblong tooling; compression force is maintained between 10–18 kN to achieve tablet hardness of 80–120 N. Turret speed is typically 25–35 rpm, and punch tips are inspected every 4 h for picking because methenamine hippurate can adhere to steel tooling when ambient relative humidity exceeds 50% RH. Environmental controls require process air at 18–25°C and <40% RH; in-line loss-on-drying after compression is specified at ≤0.8% because retained moisture accelerates localized hydrolysis. Compliance testing follows USP <905> and Ph. Eur. 2.9.40 for content uniformity, USP <711> and Ph. Eur. 2.9.3 for dissolution, USP <921> for water determination, and ICH Q3D for elemental impurities; batch release under 21 CFR 211 includes identity, assay, related substances, and water determination. The terminal finished product is an immediate-release oral tablet containing methenamine hippurate 1 g, supplied as a moisture-barrier film-coated or uncoated tablet for prophylaxis of recurrent urinary tract infections.

Table 1 consolidates the pharmacopoeial test design for high-dose methenamine hippurate tablet compression.

Capsule filling conditions for methenamine hippurate oral formulations require moisture exclusion at every transfer point

The manufacture of capsule-based methenamine hippurate oral formulations is executed under low-humidity conditions because the API can adsorb surface moisture during transfer between unit operations. When hard gelatin or HPMC shells are specified, the active is methenamine hippurate at 500 mg or 1000 mg per capsule, filled into size 00 or size 000 shells. The formulation addition ratio is adjusted by tapped density and capsule fill volume, typically using microcrystalline cellulose at 20–40% w/w, sodium starch glycolate disintegrant at 2–4% w/w, colloidal silicon dioxide at 0.5–1.0% w/w, and magnesium stearate at 0.5–1.0% w/w after each component is passed through a 0.500 mm sieve. Blending uses a 600 L IBC bin blender at 10–12 rpm for 20 min; pre-blend uniformity is verified by stratified sampling of 10 points with RSD ≤ 5.0% before lubrication. Capsule filling is conducted on a tamping pin or dosator machine at 60,000–90,000 capsules/h depending on shell format and powder bed height. Fill weight control uses in-process check weighing every 15 min against ±3% limits, and separation force is monitored on automatic empty-shell reject stations to limit partial fills. Gelatin shell moisture is maintained at 13–16%, HPMC shell at 3–7%; process rooms are kept at 20–25°C and 35–45% RH to reduce shell deformation and API adhesion to contact parts. Transfer chutes, vacuum wands, and dust collection points are grounded because methenamine hippurate dust may tribocharge in low-humidity environments and cause weight variation. Compliance references include USP <711>, USP <905>, USP <921>, USP <61>, USP <62>, and ICH Q3C for residual solvents if a prior non-aqueous granulation step is used. Disintegration is evaluated by USP <701>, and dissolution is controlled under Ph. Eur. 2.9.3. Terminal product types are immediate-release hard gelatin or HPMC capsules containing methenamine hippurate 500 mg or 1000 mg, intended for oral urinary antibacterial prophylaxis.

Non-aqueous granulation is specified for methenamine-containing oral granules when the finished dosage form is a single-dose sachet or multidose bulk granule for extemporaneous suspension reconstitution. The critical reason is that methenamine decomposes by acid-catalyzed hydrolysis in aqueous binder systems; once dissolved, the molecule can release formaldehyde, and granule potency can decrease during oven drying. The granulation vehicle is isopropyl alcohol or dehydrated ethanol, with povidone K30 dissolved at 5–10% w/w of the dry granule matrix as binder. The active addition ratio is methenamine hippurate 70–85% w/w, mannitol 10–20% w/w, crospovidone 2–4% w/w, and colloidal silicon dioxide 0.2–0.5% w/w. Granulation is performed in a top-spray fluid bed at inlet air temperature 40–50°C, product temperature 28–32°C, and dew point 4–6°C; spray rate is adjusted to 15–30 g/min per nozzle for a 300 kg batch. After drying to loss-on-drying ≤2.0%, the granules are milled through a 1.0 mm conical mill at 1500 rpm. Particle size is controlled by USP <786> sieve analysis, with D50 300–600 µm and fines below 150 µm limited to ≤15% w/w to ensure uniform sachet filling. The granule blend is filled into sachets on a vertical form-fill-seal machine with fill weight control at ±2%; sealing temperature is adjusted for polyethylene/aluminium/polyethylene terephthalate laminate to maintain moisture barrier below 0.5 g/m²/day water vapour transmission. Compliance covers USP <905>, Ph. Eur. 2.9.40, USP <711>, USP <921>, and ICH Q3D; residual isopropyl alcohol is controlled under ICH Q3C with a limit of 5000 ppm in the finished sachet granule. Terminal finished product types include single-dose oral granules packed in 1 g or 2 g sachets and multidose bulk granules for extemporaneous oral suspension reconstitution.

Sterile Injectable Methenamine Solution and Lyophilized Powder Handling Limits

Sterile injectable compounding of methenamine hippurate is performed under aseptic conditions because the molecule is not stable to terminal steam sterilization at 121°C; high-temperature aqueous exposure accelerates hydrolysis to formaldehyde and ammonia. Published data for marketed methenamine injectable finished-drug products is limited, so injectable use is predominantly encountered in compounding environments under USP <797> rather than in commercial ready-to-use vials. The compounding batch record specifies the API mass as methenamine hippurate per final volume, typically in the range of 10–50 mg/mL for hospital-prepared intravenous admixtures; concentrations above 50 mg/mL are avoided because precipitation risk increases at 20–25°C, especially after pH adjustment. Dissolution is performed in Water for Injection at 20–25°C with continuous low-shear mixing; tonicity is adjusted with sodium chloride 0.9% w/v where isotonic administration is required. The solution is filtered through a 0.22 µm polyethersulfone membrane; filter integrity is verified by bubble point at the manufacturer’s validation value, typically ≥3200 mbar for 0.22 µm PES. Sterile filling occurs in an ISO 5 laminar airflow hood within an ISO 7 cleanroom, with settle plates and contact plates monitored under EU GMP Annex 1 or equivalent. If lyophilized powder is specified, the filtered solution is filled into depyrogenated glass vials, partially stoppered, and lyophilized at a shelf freezing temperature of -40°C, primary drying at -10°C, and secondary drying at 25°C under vacuum. The final pH is maintained at 5.5–6.5 to limit acid-catalyzed degradation; below 5.5 hydrolysis accelerates, and above 6.5 the chemical stability must be confirmed by real-time assay. Endotoxin testing follows USP <85>, particulate matter follows USP <788> for large-volume injectables, and sterility testing follows USP <71>. Residual solvents from upstream processing are controlled under ICH Q3C, and elemental impurities under ICH Q3D. The terminal product type is a sterile methenamine hippurate solution or a lyophilized powder for reconstitution, prepared in single-dose vials or infusion bags for intravenous administration when oral therapy is not feasible.

When Methenamine Mandelate Replaces Hippurate in Acidifying Fixed-Dose Tablets

Fixed-dose methenamine mandelate tablets are manufactured using alcohol-based wet granulation when the acid moiety is intended to acidify the urine and promote formaldehyde release. The clinical requirement is a urinary pH below 5.5 for sufficient hydrolysis; mandelic acid contributes to this effect while forming a stable salt with methenamine. The tablet addition ratio is methenamine mandelate 500 mg or 1000 mg per tablet, representing a drug load of 75–85% w/w in the core. Because mandelic acid in the salt can create a low-pH microclimate during wet processing, the granulation vehicle is alcohol-based rather than water-based; povidone K30 at 2–4% w/w is dissolved in isopropyl alcohol and sprayed onto the dry mix in a 150–200 L high-shear mixer, with impeller speed 150 rpm and chopper speed 1500 rpm. The wet mass is dried at 40–45°C to loss-on-drying ≤2.0%, passed through a 1.0 mm oscillating granulator, and lubricated with magnesium stearate 0.5–1.0% w/w. Compression uses round or oval tooling on a 27-station rotary press; tablet hardness is controlled at 90–140 N and friability below 1.0% under USP <1216>. Tablet coating with a moisture-protective film is applied when packaging does not include desiccant; the coating layer typically adds 2–3% w/w to the core. Stability risks include granule sticking during compression when environmental relative humidity exceeds 55% RH, and localized pH drift if alkaline excipients such as calcium carbonate or magnesium oxide are introduced. Compliance references include the product-specific USP monograph, USP <711>, Ph. Eur. 2.9.3, USP <905>, and ICH Q3D. Terminal products are immediate-release methenamine mandelate tablets at 500 mg and 1000 mg, and granules for oral suspension where the acidifying salt strategy is retained.